Castle Biosciences (CSTL) said Monday it has received approval from the New York State Department of Health for its TissueCypher test, a tool designed to assess the risk of progression from Barrett's esophagus to esophageal cancer.
The company said the approval expands its New York Clinical Laboratory Permit to include this test, along with others in its dermatology, gastroenterology, and ophthalmology portfolios.
Shares of the company were up 4.2% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.